{"news_desk": "Business", "print_page": "3", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "abstract": "Institute for Clinical and Economic Review finds cholesterol-lowering drugs Repatha and Praluent are very overpriced given value they offer; report, which is used by health plans in price negotiations, could force drug makers Amgen and Sanofi to offer larger discounts.", "type_of_material": "News", "word_count": "825", "lead_paragraph": "A report from the Institute for Clinical and Economic Review says the prices on two drugs to fight cholesterol that cost more than $14,000 a year should be slashed.", "pub_date": "2015-09-09T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "New Cholesterol Drugs Are Vastly Overpriced, Analysis Says", "print_headline": "New Cholesterol Drugs Are Overpriced, Analysis Finds"}, "snippet": "A report from the Institute for Clinical and Economic Review says the prices on two drugs to fight cholesterol that cost more than $14,000 a year should be slashed.", "multimedia": [{"height": 126, "url": "images/2015/09/09/business/09drug-web1/09drug-web1-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/09/09/business/09drug-web1/09drug-web1-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 400, "url": "images/2015/09/09/business/09drug-web1/09drug-web1-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2015/09/09/business/09drug-web1/09drug-web1-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/09/09/business/09drug-web1/09drug-web1-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/09/09/business/09drug-web1/09drug-web1-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/09/09/business/new-cholesterol-drugs-are-vastly-overpriced-analysis-says.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Institute for Clinical and Economic Review", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Cholesterol", "name": "subject"}, {"rank": "4", "is_major": "Y", "value": "Amgen Inc", "name": "organizations"}, {"rank": "5", "is_major": "Y", "value": "Sanofi SA", "name": "organizations"}, {"rank": "6", "is_major": "N", "value": "Prices (Fares, Fees and Rates)", "name": "subject"}, {"rank": "7", "is_major": "N", "value": "Health Insurance and Managed Care", "name": "subject"}, {"rank": "8", "is_major": "N", "value": "Praluent (Drug)", "name": "subject"}, {"rank": "9", "is_major": "N", "value": "Repatha (Drug)", "name": "subject"}], "blog": [], "_id": "55ef520d38f0d867b4c896af", "source": "The New York Times"}